Gastrointestinal Cancer Research - Penn State Cancer Institute
Gastrointestinal Cancer Research
Research into gastrointestinal cancer at Penn State Cancer Institute is conducted by our dedicated gastrointestinal cancer team. See current clinical trials and members of that team here.
Clinical Trials
Micro/nano technology for extracellular vesicle isolation and towards non-invasive pancreatic cancer diagnosis
A Phase I/II Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C mutation (KRYSTAL-1) (MRT849-001)
The COVID-19 and Cancer Consortium (CCC19) Registry
Prospective evaluation of potential effects of repeated gadoliniumbased contrast agent (GBCA) administrations of the same GBCA on motor and cognitive functions in neurologically normal adults in comparison to a non-GBCA exposed control group ODYSSEY
EA2197: Optimal Perioperative Therapy For Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial
A Phase 1b/2, Dose-escalation, Randomized, Multicenter Study of Maintenance Ivaltinostat plus Capecitabine or Capecitabine Monotherapy in Patients with Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on First Line FOLFIRINOX Chemotherapy
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US) (NRG-GI008)
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors
Cancer biobank for developing novel diagnostic biomarkers and therapeutic targets
The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing The Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients With Locally Advanced Rectal Cancer
Measuring changes in knowledge, perception of benefit, susceptibility, severity, and self-efficacy of community outreach colorectal cancer and colorectal cancer screening education in underserved populations: a survey study.
Disease Team Members
| First Name | Last Name | Title | Role | ||
|---|---|---|---|---|---|
 |
Amanda | Cooper | MD | ||
 |
Michael | Deutsch | MD | ||
 |
Walter | Koltun | MD | ||
 |
Abraham | Mathew | MD | ||
 |
Matthew | Moyer | MS, MD | ||
 |
Nabeel | Sarwani | MD | ||
 |
Ian | Schreibman | MD | ||
 |
Jeffrey | Scow | MD | ||
 |
Leonard | Tuanquin | MD | ||
 |
Nelson Shu-Sang | Yee | MD, PhD, RPh |
Research into gastrointestinal cancer at Penn State Cancer Institute is conducted by our dedicated gastrointestinal cancer team. See current clinical trials and members of that team here.
Micro/nano technology for extracellular vesicle isolation and towards non-invasive pancreatic cancer diagnosis
A Phase I/II Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C mutation (KRYSTAL-1) (MRT849-001)
The COVID-19 and Cancer Consortium (CCC19) Registry
Prospective evaluation of potential effects of repeated gadoliniumbased contrast agent (GBCA) administrations of the same GBCA on motor and cognitive functions in neurologically normal adults in comparison to a non-GBCA exposed control group ODYSSEY
EA2197: Optimal Perioperative Therapy For Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial
A Phase 1b/2, Dose-escalation, Randomized, Multicenter Study of Maintenance Ivaltinostat plus Capecitabine or Capecitabine Monotherapy in Patients with Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on First Line FOLFIRINOX Chemotherapy
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US) (NRG-GI008)
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors
Cancer biobank for developing novel diagnostic biomarkers and therapeutic targets
The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing The Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients With Locally Advanced Rectal Cancer
Measuring changes in knowledge, perception of benefit, susceptibility, severity, and self-efficacy of community outreach colorectal cancer and colorectal cancer screening education in underserved populations: a survey study.
| First Name | Last Name | Title | Role | ||
|---|---|---|---|---|---|
|
Amanda | Cooper | MD | ||
|
Michael | Deutsch | MD | ||
|
Walter | Koltun | MD | ||
|
Abraham | Mathew | MD | ||
|
Matthew | Moyer | MS, MD | ||
|
Nabeel | Sarwani | MD | ||
|
Ian | Schreibman | MD | ||
|
Jeffrey | Scow | MD | ||
|
Leonard | Tuanquin | MD | ||
|
Nelson Shu-Sang | Yee | MD, PhD, RPh |